Coave Therapeutics is focused on advancing gene therapies for rare ocular and CNS diseases using their AAV-Ligand Conjugates platform (ALIGATER). Their goal is to improve the effectiveness of advanced gene therapies by enabling targeted delivery and enhanced gene transduction. By targeting diseases with a clear unmet need, Coave Therapeutics aims to rapidly validate their ALIGATER platform and provide life-changing treatments for patients.